Records 1 - 7
| A randomized phase II study of S-1 versus capecitabine as first-line chemotherapy in elderly metastatic gastric cancer patients with or without poor performance status: clinical and pharmacogenetic results.
Pharmacogenetics and genomics 2017 Nov .
Kim Mi-Jung, Kong Sun-Young, Nam Byung-Ho, Kim Sohee, Park Young-Iee, Park Sook Ry
| A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2015 Apr .
Kim Young-Woo, Kim Mi-Jung, Ryu Keun Won, Lim Hyeong-Seok, Lee Jun Ho, Kong Sun-Young, Lee Jong Seok, Choi Il Ju, Kim Chan Gyoo, Lee Jong Yeul, Cho Soo-Jeong, Kook Myeong-Cherl, Park Young-Iee, Kim Seok-Ki, Park Sook Ry
| Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
Cancer chemotherapy and pharmacology 2013 Nov 72 (5): 953-64.
Park Sook Ryun, Hong Yong Sang, Lim Hyeong-Seok, Seong Moon-Woo, Kong Sun-Young, Kim Sun Young, Park Young-Iee, Jung Kyung H
| S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis.
British journal of cancer 2013 Sep 109 (6): 1420-7.
Kim S Y, S Hong Y, K Shim E, Kong S-Y, Shin A, Baek J Y, Jung K
| A Phase II study of clinical outcomes of 3-week cycles of irinotecan and S-1 in patients with previously untreated metastatic colorectal cancer: influence of the UGT1A1 and CYP2A6 polymorphisms on clinical activity.
Oncology 2012 82 (5): 5.
Choi YH, Kim TW, Kim KP, Lee SS, Hong YS, Ryu MH, Lee JL, Chang HM, Ryoo BY, Kim HS, Shin JG, Kang YK
| Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity.
British journal of cancer 2011 Feb 104 (4): 605-12.
Kim K-p, Jang G, Hong Y S, Lim H-S, Bae K-s, Kim H-S, Lee S S, Shin J-G, Lee J-L, Ryu M-H, Chang H-M, Kang Y-K, Kim T
| [Validation of genetic polymorphisms associated to the toxicity of chemotherapy in colorectal cancer patients].
Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria 0 38 (4): 283-90.
Cortejoso L, García M I, García-Alfonso P, Grávalos C, Robles L, González-Haba E, Sanjurjo M, López-Fernández L